Last reviewed · How we verify
NCT06558253
The Safety and Efficacy of Coenzyme I for Injection in Promoting Hematopoietic Recovery of Patients After sUCBT
Phase 1 trial testing Coenzyme I for Injection in Hematopoietic Recovery in 12 participants. Currently enrolling.
1 April 2026
Quick facts
| Lead sponsor | Anhui Provincial Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 29 November 2024 |
| Primary completion | 1 April 2026 |
| Estimated completion | 30 September 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Coenzyme I for Injection — full drug profile →
Conditions studied
- Hematopoietic Recovery — all drugs for Hematopoietic Recovery →
Sponsor
Anhui Provincial Hospital
Who can join
Adults 18 to 60, any sex, with Hematopoietic Recovery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To assess the safety and efficacy of coenzyme I for injection in promoting hematopoietic recovery after single-unit unrelated cord blood transplantation in hematological malignancies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06558253
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Coenzyme I for Injection
Trials testing the same drug.
- NCT07328100 — Efficacy and Safety of Coenzyme I for Injection on Vascular Aging. · NA · not yet recruiting
Other Anhui Provincial Hospital trials
Trials by the same sponsor.
- NCT07523464 — Centrally Confined 8Gy/1f to Tumor Core Followed by Concurrent Chemoradiotherapy for Unresectable Stage III NSCLC · Phase 1 · not yet recruiting
- NCT07481656 — Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT) · Phase 4 · not yet recruiting
- NCT07462676 — Simultaneous Vs Staged VPS and CP :A Multi-cnter RCT. · NA · not yet recruiting
- NCT07211048 — Anti CD19 Gene Therapy for B-cell Lymphoma · NA · recruiting
- NCT07279844 — An Open-label, Observational, Long-term Follow-up Study Evaluating the Safety and Efficacy of RGL-193 Putamen Injection · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06558253 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Anhui Provincial Hospital
- Last refreshed: 18 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06558253.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing